Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway

doi:10.1016/j.canlet.2019.02.042

	Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway
	Shao, Jialiang 7,8; Zhu, Wencheng 4; Ding, Yufeng 5; Zhu, Hongwen 6; Jing, Xiaoqian 1; Yu, Hua 7; Lu, Mujun 5; Qiao, Yunbo 7; Wang, Xiang 8; Ai, Hua 2,3
刊名	CANCER LETTERS
	2019
卷号	451 页码:110-121
关键词	LIFR Phosphorylation Prostate cancer AKT
ISSN号	0304-3835
DOI	10.1016/j.canlet.2019.02.042
通讯作者	Zhu, Hongwen(zhw@simm.ac.cn) ; Qiao, Yunbo(ybqiao@gzhu.edu.cn) ; Wang, Xiang(drseanwang@163.com) ; Wang, Xiongjun(xjwang02@sibcb.ac.cn)
英文摘要	Prostate cancer (PCa) is the most common solid organ malignancy among men, outnumbering both lung and colorectal cancer, and it is the second leading cause of male tumor-related death in the United States due to high metastasis. Recently, leukemia inhibitory factor receptor (LIFR) has been found to play roles in multiple types of cancer. However, the roles of LIFR in the progression of PCa remain to be revealed. In this study, we found that LIFR plays an oncogenic role in PCa. The phosphorylation of LIFR at 51044 contributes to subsequent activation of the AKT pathway, inducing the expression of a series of proliferation and metastatic genes. Additionally, LIFR-S1044 is phosphorylated by ERK2 but not EFtKl. The signal intensity of pLIFR-S1044 and pAKT 5473 in PCa tissue displays a tight positive correlation. The ERK2/LIFR/AKT axis modulates PCa progression and offers a promising therapeutic and diagnostic target for PCa.
资助项目	Hundred Talent Program of Guangzhou University ; National Natural Science Foundation of China[81570607] ; National Natural Science Foundation of China[81170697] ; Shanghai Shenkang Hospital Development Center Fund[16CR2003A]
WOS关键词	LEUKEMIA-INHIBITORY FACTOR ; FACTOR-RECEPTOR ; METASTASIS SUPPRESSOR ; INTERLEUKIN-6 FAMILY ; SOLUBLE FORM ; GROWTH ; CELLS ; IDENTIFICATION ; EXPRESSION ; CYTOKINES
WOS研究方向	Oncology
语种	英语
出版者	ELSEVIER IRELAND LTD
WOS记录号	WOS:000464297000011
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/290100]
专题	中国科学院上海药物研究所
通讯作者	Zhu, Hongwen; Qiao, Yunbo; Wang, Xiang; Wang, Xiongjun
作者单位	1.Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Surg, Shanghai 200025, Peoples R China 2.Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610065, Sichuan, Peoples R China 3.Sichuan Univ, West China Hosp, Dept Radiol, Chengdu 610065, Sichuan, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China 5.Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Urol & Androl, Shanghai 200001, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 7.Guangzhou Univ, Sch Life Sci, Precise Genome Engn Ctr, Guangzhou 510006, Guangdong, Peoples R China 8.Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Urol, Shanghai 200080, Peoples R China
推荐引用方式 GB/T 7714	Shao, Jialiang,Zhu, Wencheng,Ding, Yufeng,et al. Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway[J]. CANCER LETTERS,2019,451:110-121.
APA	Shao, Jialiang.,Zhu, Wencheng.,Ding, Yufeng.,Zhu, Hongwen.,Jing, Xiaoqian.,...&Wang, Xiongjun.(2019).Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway.CANCER LETTERS,451,110-121.
MLA	Shao, Jialiang,et al."Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway".CANCER LETTERS 451(2019):110-121.